New reference pricing groups to hit industry in Spain
This article was originally published in Scrip
13 new groups of medicines will be subject to reference pricing next year in Spain, says a draft ministerial order. This and other measures are likely to cost the industry around €400 million a year.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.